Oral News and Research

RSS

SCYNEXIS, MMV assemble Malaria Box of 400 compounds with antimalarial activity

In a bid to catalyse malaria and neglected disease drug discovery, MMV and SCYNEXIS, Inc. have assembled a Malaria Box of 400 carefully selected commercially available compounds with antimalarial activity and will provide it to researchers at no cost.

20 Dec 2011

Top-line results from Genzyme's teriflunomide and Rebif Phase III comparison trial on RMS

Genzyme, a Sanofi company, today reported top-line results from TENERE, a Phase III clinical trial comparing the effectiveness, safety and tolerability of once-daily oral teriflunomide to interferon beta-1a, an approved injectable therapy, in people with relapsing forms of multiple sclerosis.

20 Dec 2011

Fluoride supplements not found to be safe or effective

According to the Cochrane Oral Health Group, fluoride supplements fail to reduce tooth decay in primary teeth, permanent teeth cavity-reduction is dubious and health risks are little studied.

19 Dec 2011

Newgen acquires novel oncology development programs from Kanion

NewGen Therapeutics, Inc. today announced the acquisition of three novel oncology development programs from Kanion USA, Inc. and Kanion Pharmaceutical Co., Ltd..

19 Dec 2011

Alkermes commences ALKS 9070 phase 3 clinical trial for schizophrenia

Alkermes plc today announced the initiation of a phase 3 clinical trial of ALKS 9070 for the treatment of schizophrenia. ALKS 9070, a proprietary Alkermes molecule, is designed to provide patients with once-monthly dosing of a medication that, once in the body, converts into aripiprazole, a molecule that is commercially available under the name ABILIFY for the treatment of a number of central nervous system disorders.

19 Dec 2011

Zalicus commences Z944 Phase 1 clinical trial for treatment of acute and inflammatory pain

Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced the initiation of a Phase 1 clinical trial evaluating the pharmacokinetics and safety of Z944, a novel oral T-type calcium channel blocker with demonstrated preclinical potential for the treatment of acute and inflammatory pain.

19 Dec 2011

Study: Dentists' role in medical checkups

A study in the American Journal of Public Health indicates that many people who don't have regular contact with a physician still see a dentist at least once a year -- potentially positioning these professionals to spot the early signs of chronic illnesses.

17 Dec 2011

F. nucleatum alters endothelial integrity and allows other bacteria to invade human body

A common oral bacteria, Fusobacterium nucleatum, acts like a key to open a door in human blood vessels and leads the way for it and other bacteria like Escherichia coli to invade the body through the blood and make people sick, according to dental researchers at Case Western Reserve University.

16 Dec 2011

Wistar to develop new drug against EBV-associated cancers

The Wistar Institute today announced that it has signed a funding agreement with the Wellcome Trust, a United Kingdom-based charity, to support the development of a new drug to treat cancers associated with Epstein-Barr virus.

16 Dec 2011

Study evaluates use of leukocyte and platelet-rich fibrin biomaterial in heart patients

Cardiac patients that take anticoagulant medications and need a tooth extraction face an increased risk of bleeding that must be addressed by the treating clinician. Therefore, a protocol for heart patients is needed that will avoid significant bleeding after dental extractions without suspending anticoagulant therapy.

15 Dec 2011

New drug candidate may halt mental decline of Alzheimer's

A new drug candidate may be the first capable of halting the devastating mental decline of Alzheimer's disease, based on the findings of a study published today in PLoS one.

15 Dec 2011

FDA approves modernized labeling for ViroPharma's Vancocin Capsules

ViroPharma Incorporated today announced the modernization of labeling for Vancocin (vancomycin hydrochloride, USP) Capsules made effective through the U.S. Food and Drug Administration's (FDA) approval of a supplemental new drug application.

15 Dec 2011

Experts warn expectant moms about dangers of common cold medicines during pregnancy

Experts in pregnancy and breastfeeding health at the California Teratogen Information Service (CTIS) Pregnancy Health Information Line warn expectant moms about the potential dangers of common cold medicines during pregnancy.

15 Dec 2011

$Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL$

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Celgene International Sàrl, a subsidiary of Celgene Corporation, (NASDAQ: CELG), announced final results from a phase II investigational study evaluating the combination of REVLIMID® (lenalidomide) and rituximab in 59 patients with relapsed or refractory chronic lymphocytic leukemia (CLL). These data were presented at the 53rd Annual Meeting of the American Society of Hematology in San Diego, CA.

14 Dec 2011

Positive data from Nektar's NKTR-181 Phase 1 clinical study for chronic pain

Nektar Therapeutics today announced positive data from a Phase 1 clinical study of NKTR-181 evaluating multiple ascending oral doses of NKTR-181 over an 8-day treatment period in healthy subjects.

14 Dec 2011

TV cameras and the Supreme Court: Health law adds pressure to the mix

Now that the Supreme Court has agreed to hear a dispute over the federal health care law, the justices are facing the strongest challenge to their ban on televised hearings. Members of Congress and news industry leaders have asked the court to allow the televising of oral arguments, to be held over five and a half hours during two days in March.

14 Dec 2011

CTI, Chroma announce final results from tosedostat phase II study on AML

Cell Therapeutics, Inc. and Chroma Therapeutics Ltd. announced that final results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) were presented by Jorge Cortes, M.D. of the University of Texas M.D. Anderson Cancer Center during the Acute Myeloid Leukemia - Therapy, excluding Transplantation: Clinical Studies session at the American Society of Hematology Annual Meeting.

14 Dec 2011

NYUCI experts present latest research findings about hematologic cancers at 53rd ASH meeting

Experts from the NYU Cancer Institute, an NCI-designated cancer center at NYU Langone Medical Center, presented their latest research findings about hematologic cancers at the 53rd ASH Annual Meeting and Exposition held December 10-13, 2011 in San Diego, California.

14 Dec 2011

Incyte announces further analyses from Jakafi Phase III trial on myelofibrosis

Incyte Corporation today announced that further analyses from the global, pivotal Phase III clinical program of Jakafi (ruxolitinib or INC424) are being presented at the 2011 American Society of Hematology (ASH) Annual Meeting.

13 Dec 2011

First Edition: December 13, 2011

Kaiser Health News staff writer Phil Galewitz talked with former Centers for Medicare and Medicaid Services Administrator Donald Berwick, who defended these federal health programs, but said they are trapped in a U.S. health system that promotes wasteful spending and inefficient care.

13 Dec 2011

Oral News and Research

SCYNEXIS, MMV assemble Malaria Box of 400 compounds with antimalarial activity

Top-line results from Genzyme's teriflunomide and Rebif Phase III comparison trial on RMS

Fluoride supplements not found to be safe or effective

Newgen acquires novel oncology development programs from Kanion

Alkermes commences ALKS 9070 phase 3 clinical trial for schizophrenia

Zalicus commences Z944 Phase 1 clinical trial for treatment of acute and inflammatory pain

Study: Dentists' role in medical checkups

F. nucleatum alters endothelial integrity and allows other bacteria to invade human body

Wistar to develop new drug against EBV-associated cancers

Study evaluates use of leukocyte and platelet-rich fibrin biomaterial in heart patients

New drug candidate may halt mental decline of Alzheimer's

FDA approves modernized labeling for ViroPharma's Vancocin Capsules

Experts warn expectant moms about dangers of common cold medicines during pregnancy

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Positive data from Nektar's NKTR-181 Phase 1 clinical study for chronic pain

TV cameras and the Supreme Court: Health law adds pressure to the mix

CTI, Chroma announce final results from tosedostat phase II study on AML

NYUCI experts present latest research findings about hematologic cancers at 53rd ASH meeting

Incyte announces further analyses from Jakafi Phase III trial on myelofibrosis

First Edition: December 13, 2011

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News